Home » Agenix Sells Milton Pharmaceuticals, Focuses on Molecular Imaging
Agenix Sells Milton Pharmaceuticals, Focuses on Molecular Imaging
The Brisbane-based Biotechnology company, Agenix Ltd., has sold its Milton Pharmaceuticals subsidiary, freeing management and financial resources to build Agenix's molecular imaging pipeline. Settlement will take place Feb. 28, a company release said. Molecular imaging, which involves the targeted and functional detection of diseases such as cancer and metabolic diseases, is being hailed as the future direction of imaging medicine. The companies like Agenix, GE, Philips and Siemens involved in the area.
Pharmabiz (http://www.pharmabiz.com/article/detnews.asp?articleid=26332§ionid=)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct